Pfizer advances once-daily weight-loss pill in ongoing study
What is Pfizer's new weight-loss pill called?
Pfizer's new weight-loss pill is called danuglipron. It is a once-daily oral treatment and is the most advanced of Pfizer's obesity drug candidates. The company plans to conduct tests later this year to determine the ideal dose of the drug2.
How many clinical candidates does Pfizer have?
Pfizer has three clinical candidates in its pipeline for obesity drugs. The most advanced of them is danuglipron, a once-a-day oral treatment. The company plans to conduct tests later this year to determine the ideal dose of the drug. Pfizer is aiming to tap into the highly lucrative market for obesity drugs, which is projected to surpass $100 billion in 2030.
Which companies currently dominate the obesity drug market?
Eli Lilly and Novo Nordisk currently dominate the obesity drug market with their respective medications, Ozempic and Wegovy. These drugs have shown significant potential in treating obesity and are considered highly effective in promoting weight loss.